This study is being done to test the safety of elraglusib when taken once a day and to assess:
* How the body processes the drug (pharmacokinetics) * Assess potential effects of the drug on heart rhythm * Find the highest daily dose that can be given without causing side effects
Able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures
Age ≥ 18 years
Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition
Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit
Pregnant or lactating
Known to be hypersensitive to any of the components of elraglusib tablets or to the excipients used in its formulation
Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and/or infertility. Recovery is defined as ≤ Grade 2 severity per Common Terminology Criteria for Adverse Events (CTCAE), v6.0
A history of Torsade de pointes (TdP), other ventricular arrhythmias, or long QT syndrome